Key result
Lower baseline uEGF correlates with greater annual declines in cardiovascular autonomic neuropathy indices.
Why the study?
The relationship between urinary endothelial growth factor and cardiovascular autonomic neuropathy in adults with type 1 diabetes was not well characterized.
Do baseline urinary endothelial growth factor levels correlate with cardiovascular autonomic neuropathy indices in adults with type 1 diabetes?
Cohort (n=44)
Do baseline urinary endothelial growth factor levels correlate with cardiovascular autonomic neuropathy indices in adults with type 1 diabetes?
p-value: p=0.01
Baseline urinary EGF levels correlate with baseline and longitudinal changes in cardiovascular autonomic neuropathy indices in adults with type 1 diabetes, suggesting potential utility as a biomarker.
Lower uEGF may flag CAN risk in type 1 diabetes; hypothesis-generating and requires larger prospective validation before any clinical role.
The relationship between urinary endothelial growth factor (uEGF) and cardiovascular autonomic neuropathy (CAN) in adults with type 1 diabetes was evaluated. uEGF levels at baseline and standardized CAN measures were collected at baseline and annually for 3 years for type 1 diabetes adults. Linear regression analysis and linear mixed effects model were used for analysis. In this cohort (n = 44, 59% women, mean ± standard deviation age 34 ± 13 years and diabetes duration 14 ± 6 years), lower baseline uEGF levels correlated with lower baseline expiration : inspiration ratios (P = 0.03) and greater annual declines in Valsalva ratios (P = 0.02) in the unadjusted model, and correlated with lower low-frequency power : high-frequency power ratios (P = 0.01) and greater annual changes in low-frequency power : high-frequency power ratios (P = 0.01) after adjustment for age, sex, body mass index, and hemoglobin A1C. In conclusion, baseline uEGF levels correlate to baseline and longitudinal changes in CAN indices. A large-scale, long-term study is needed to validate uEGF as a reliable CAN biomarker.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2023) conducted a cohort in Type 1 diabetes (n=44). Urinary epidermal growth factor (uEGF) levels was evaluated on Cardiovascular autonomic neuropathy (CAN) indices (p=0.01). Lower baseline urinary epidermal growth factor levels correlated with greater annual declines in Valsalva ratios (P=0.02) and changes in low-frequency to high-frequency power ratios (P=0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: